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ABSTRACT
Synthesis of Resveratrol Ester Derivatives Using Selective Enzymatic Hydrolysis
by
Marian Osei – Mensah
Resveratrol, a naturally derived stilbene, is an interesting compound mostly talked about recently
because for its anti-cancer properties. Unfortunately it has some shortcomings due to its low
bioavailability and low solubility in water. For this reason, my research is to overcome
resveratrol’s drawbacks by improving its bioavailability and hydrophilicity. My research is
focused on syntheses of novel derivatives of resveratrol such as 3, 5-di-O-isobutyroyl resveratrol
and 3, 5-di-O-hexanoyl resveratrol using lipase catalyzed hydrolysis. Therefore, the tri-acylated
resveratrols 3, 5, 4’-tri-O-isobutyroyl resveratrol and 3, 5,4’-tri-O-hexanoyl resveratrol were first
synthesized.

3,5,4’-tri-O-isobutyroyl resveratrol and 3,5,4’-tri-O-hexanoyl resveratrol were then hydrolyzed
using lipase (C. Antarctica) to obtain the products 3,5-di-O-isobutyroyl resveratrol and 3,5-di-Ohexanoyl resveratrol. The four compounds 3,5-di-O-isobutyroyl resveratrol, 3,5-di-O-hexanoyl
resveratrol, 3,5,4’-tri-O-hexanoyl resveratrol, and 3,5-di-O-hexanoyl resveratrol were
characterized by 1H NMR and 13C NMR.
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CHAPTER 1
INTRODUCTION
Resveratrol (3, 5, 4’-trihydroxy-trans-stilbene) occurs in nature as a phytoalexin that is
produced by several plants as a result of environmental pressure or pathogenic attack. It can be
found in grapes, peanuts, mulberries, and blueberries.1-3 Considerable amounts of resveratrol can
be found in wine as a result of its concentrated amount in grape skin.4, 5 Research has shown that
red wine minimizes the risk of cardiovascular disease. 6-9 Resveratrol has various biological
behaviors such as antioxidant,10 anti-inflammatory ,11-13 anti-ischemic,14-16 neuroprotective,17,18
anti-aging,19-21 antiobesity,22 antiviral,23 cardioprotective,24-26 anticancer,27 and cancer
chemopreventive effects.1,28-30 Resveratrol was found to hinder all the three stages of
carcinogenesis: initiation, promotion, and progression.1
Stilbene derivatives like resveratrol and all other naturally occurring phenolic
antioxidants are compounds with two benzene rings connected to each other by ethylene.
Currently, more interest has been directed to the development of possible approaches to
transform and to improve the functional properties of natural antioxidants without changing the
functionality responsible for the biological behavior. For instance, there has been an
improvement of the hydrophobicity of antioxidant phenolic acids by esterifying the carboxylic
acid moiety of the phenolic acid with a fatty alcohol by enzymatic and chemical methods. 31
Phenethyl alcohols have also been lipophilized by esterifying the alcoholic group with acid
chlorides or acid anhydrides.32 Thus amphiphilic phenolic compounds were acquired and their
function is to disseminate between the aqueous phase and the liphophilic phase and interact with
an emulsifier at the interface. It has lately been accounted that these compounds are potentially
remarkable for probable applications in nanotechnology. 33
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A number of acylated derivatives of resveratrol were found to be of higher cell-growth
prevention with regard to DU- 145 human prostate cancer cells than resveratrol itself.34
However, a property of resveratrol that hinders the therapeutic applications is its limited
bioavailability due to its quick metabolism in the liver that converts the resveratrol into lessactive 3-sulfate and 3-glucuronide derivatives.35 As a result, a serum half life of 8-14 min has
been reported for resveratrol.36 An appropriate way to improve bioavailability is to have
resveratrol derivatives that cannot be sulfated or glucuronated. In view of that, much attention is
noted for the regioselective modification of the 3-OH’s.35
Resveratrol is a symmetric molecule so the phenolic group at positions 3 and 5 are
chemically equivalent and they have very similar reactivity with the phenolic group at position 4,
so a special selectivity of enzymes 37 is being used for its regiospecific acylation 34 and
oxidation.38 Regioselective acylation or deacylation catalyzed by lipases in organic solvents have
especially been applied to polyphenolic compounds as a biocatalysed reaction to successfully
answer many challenging standardized chemical reactions of regioselective derivatisation of
polyhydroxylated compounds.39-43
History and Discovery of Resveratrol
Resveratrol as shown in (Figure 1) was first discovered in the 1940s in a variety of roots
in both Japan and China and these roots were dried and then functioned as medicines. The dried
root products were used to cure numerous skin infections such as athlete’s foot.
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Figure 1. Structure of Resveratrol
During 1976, resveratrol was found in the skin and seeds of grapes but not the flesh. As
said by one researcher, the fresh grape skins contain 50-100 mg resveratrol per gram, and the
concentration in wine varies from 0.2 mg/L to 7.7 mg/L.
The French paradox gave rise to the research on the advantages of resveratrol because it
is in relation to the drinking of wine in France and the minimal rate of cardiovascular problems
among the French inhabitants. The outcome of resveratrol in red wines was as a result of this
effect.44
Biological Activity of Resveratrol
Resveratrol has several major biological activities but here we discuss some of the most
recent studies and applications in that field.
Bioavailability is the rate at which a drug or a medication or other substance is absorbed
or becomes accessible at the targeted position in the body, and because living organisms
response depends on bioavailability the ability of intestines to take up resveratrol was
demonstrated over 15 years ago by health benefits. This was acquired by orally administered
resveratrol and it was first tested on rats and it prevented liver injury in rats fed peroxidized oil.26
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Bertelli et al.45 showed that some of resveratrol in red wine (6.5 mg/L in cis and trans forms) was
taken up by rats. Several tests with significant amount of 26 µg resveratrol or ingestion of 13 µg
resveratrol on daily basis over 15 days proved that the compound rapidly went into the blood
stream and may possibly be identified in high concentrations in plasma and several organs. The
same group of authors advanced their research in plasma kinetics and bioavailability of red wine
resveratrol dispensed by an intragastric tube (28 µg per rat). The group explained
pharmacokinetics by an open one- or two-compartment structure and found a considerable
cardiac bioavailability and a strong affinity for the liver and the kidneys. 46 In a different study,
Bertelli et al.47 demonstrated that a moderate amount of resveratrol was pharmacologically
effective in vitro as well as vivo. They therefore proposed that, continuing drinking wine for a
long period of time allows the drinker to take in adequate amount of resveratrol which in turn
explains the benefits of red wine on the human health.
Anticancer
Cancer is the unrestrained enlargement of irregular cells in the body. Cancer is the main
cause of mortality in humans, killing more than 6 million people annually worldwide. It happens
when a cell’s gene mutations make the cell incapable of correcting damaged DNA and unable to
commit suicide.48 Carcinogens are a group of substances that are accountable for damaging
DNA, advancing or supporting cancer. Some examples of carcinogens are tobacco, arsenic,
asbestos, radiation such as gamma and x-rays, the sun, and compounds in car exhaust fumes. 48
When our bodies are bare to these carcinogens, free radicals are produced and therefore make an
effort to take electrons from several molecules in the body. The free radicals formed however
destroy cells and have an effect on their capacity to perform normally.48
14

Age is also another risk for cancer. As we grow older, there is a rise in the cancer-causing
mutations in our DNA. Again a number of viruses have been related to cancer such as human
papillomavirus (a cause of cervical cancer), hepatitis B and C (causes of liver cancer), and
Epstein-Barr virus (a cause of some childhood cancers). Human immunodeficiency virus (HIV)
and anything for that matter that restrains or weakens the immune system inhibits the body’s
capability to fight diseases and enhances the risk of developing cancer. 48 Lastly cancer can be the
outcome of genetic trend as a result of hereditary. Cancer can however be classified in five main
groups.48
1. Carcinomas are represented by cells that cover up the internal and external parts of the
body such as lung, breast, and colon cancer.
2. Sarcomas are represented by cells that are found in the bone, cartilage, fat, connective
tissue, muscle, and other supportive tissues.
3. Lymphomas are cancers that start in the lymph nodes and immune system tissues.
4. Leukemias are cancers that commence in the bone marrow and often build up in the
bloodstream.
5. Adenomas are cancers that happen in the thyroid, the pituitary gland, the adrenal gland,
and other glandular tissues.
The treatment of cancer is based on the type of cancer and the stage it has reached and can be put
into six categories: surgery, radiotherapy, chemotherapy, immunotherapy, hormone therapy, or
gene therapy.
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Surgery
It is recognized as the oldest treatment of cancer and it can be used to completely cure a
patient by surgically removing the cancer from the body if the cancer has not metastasized. This
is frequently observed in the getting rid of the prostate or a breast or testicle. However it is
almost never possible to get rid of all the cancer cells after the disease has spread. Surgery
possibly will as well be involved in aiding to regulate signs for instance bowel obstruction or
spinal cord compression.48
Radiotherapy
This is a radiation treatment that damages cancer cells by concentrating high-energy rays on
the cancer cells. It results in damaging the molecules that constitute the cancer cells and lead the
cells to commit suicide. Radiation treatment makes use of high-energy gamma-rays that are
emitted from metals, for example radium, or high-energy x-rays that are produced in a distinctive
machine. Initial radiation treatments brought about serious consequences for the reason that the
energy beams would destroy normal, healthy tissue; however, technologies have enhanced so
that beams can be more precisely targeted. Radiation treatment functions as an individual
treatment to minimize a tumor or to damage cancer cells (as well as those related to leukemia
and lymphoma) and again used collectively in addition to several cancer treatments.48
Chemotherapy
Chemotherapy makes use of chemicals that meddle with the cell separation method –
destroying protein or DNA – in order that cancer cells will commit suicide. The treatments aim
at any fast dividing cells (not actually cancer cells), but healthy cells more often than not can
16

recuperate from any chemical-induced damage whereas cancer cells cannot. Chemotherapy is
usually employed to cure cancer that has multiplied or metastasized because the medicines move
all over the whole body. It is also an essential therapy for various kinds of leukemia and
lymphoma. Chemotherapy treatment happens in phases, hence the body has longer period for
healing between doses. Nevertheless, there are still familiar consequences such as hair loss,
nausea, fatigue, and vomiting. Combination therapies usually comprise several forms of
chemotherapy or chemotherapy combined with other treatment preferences.48
Immunotherapy
Immunotherapy seeks to make the body’s immune system battle the tumor. Local
immunotherapy infuses medication into the affected part, for instance, to bring about
inflammation that allows a tumor to contract. Systematic immunotherapy treats the entire body
by dispensing a drug such as protein interferon alpha that can contract tumors. Moreover,
immunotherapy can be regarded as non-specific if it enhances cancer fighting-capabilities by
motivating the whole immune system, and it can be regarded as targeted if the treatment
purposely informs the immune system to damage cancer cells. These therapies are comparatively
new; however, scientists have had achievement with treatments that introduces antibodies into
the body that prevent the growth of breast cancer cells. Another type of immunotherapy is bone
marrow transplantation for the reason that the contributor’s immune cell will frequently attack
the tumor that is available in the host.48
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Hormone Therapy
This is aimed to correct hormone formation in the body in order that cancer cells prevent
developing or are destroyed entirely. Several cancer cells have been associated with various
types of hormones, particularly breast and prostate cancer. Breast cancer hormone therapies
usually concentrate on decreasing estrogen levels (a typical drug generally used is tamoxifen),
whereas prostate cancer hormone therapies usually concentrate on lowering testosterone levels.
Additionally, some leukemia and lymphoma situations can be cured with the hormone
cortisone.48
Gene Therapy
Gene therapy’s objective is to replace damaged genes with ones that work to tackle the
root cause of cancer, damage to DNA. For example, researchers are making an effort to replace
the damaged gene that signals cells to stop dividing (the p53 gene) with a copy of working gene.
Other gene-based therapies concentrate on further damaging cancer cell DNA to the point where
the cell commits suicide. Gene therapy is an extremely new field and has so far not produced any
success in treatments.
Three decades of research have revealed that cancer is easier to prevent than to treat.
Food consumption provides various nutrients essential for life and good health as a whole.
Certain daily diets that include specific nutrients may help decrease the danger of acquiring
cancer. Chemoprevention is the prevention of cancer that is achieved by ingestion of chemical
agents that lower the danger of carcinogenesis,49 and it is one of the shortest ways to lessen
cancer. Some of chemopreventive agents are nonsteriodal anti-inflammatory drugs (NSAIDs)
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for instance aspirin, indomethacin, piroxicam, and sulindac all of which inhibit cyclooxygenase
(COX).50 COX acts as a catalyst in the conversion of arachidonic acid to pro-inflammatory
substances such as prostaglandins that can promote tumor cell growth and reduce the immune
system.51 Moreover, COX can trigger carcinogens that destroy genetic material.52
The discovery of resveratrol was as a result of the search for new chemopreventive
agents. On the basis of bioassay-guided fractionation of plant extract gathered in Peru,
resveratrol was known to be a strong COX inhibitor. 1 The technique of the chemical
carcinogenesis can be grouped into three main stages and the chemopreventive agents have been
classified along with the stage they inhibit.53 The stages resveratrol inhibits are tumor initiation,
promotion, and progression.
Anti-Diabetic Effects
Researchers have revealed that resveratrol has hypoglycemic and hypolipidemic effects
in both streptozotocin (STZ)-induced diabetes and STZ-nicotinamide-induced diabetes in rats.
Resveratrol improves the frequent diabetes symptoms such as polydipsia, polyphagia, and body
weight loss.54Another research performed by Sirtris Pharmaceutical Inc. demonstrated that in
human clinical trials, resveratrol reduced the blood sugar levels in both Phase Ib and Phase IIa. 55
Anti-Viral Effects
Studies demonstrate that resveratrol inhibits herpes simplex virus (HSV) types 1 and 2
replication by blocking of an early stage in the virus replication cycle. Research in mice in vivo
reveals that resveratrol inhibits or lowers HSV replication in the vagina and as a result reduces
extra-vaginal disease. It was evident that animals whose skins were healed with resveratrol
19

demonstrated no dermal contamination or toxicity such as scaling, erythema, crushing,
lichenification, or excoriation.56 Research also reveals that resveratrol inhibits varicella-zoster
virus, specific influenza virus, respiratory viruses, and human cytomegalovirus. Moreover,
resveratrol works with and improves the anti-HIV-activity of some anti-HIV drugs.57
Mechanism of Action
Resveratrol has numerous beneficial effects, but the mechanism of action is not yet clear,
although several direct targets have been discovered for it. Resveratrol exhibits antioxidant
properties by the addition of exogenous red wine dilutions in aqueous environment to isolated
LDL in a buffer solution.58 Resveratrol additionally exhibits anti-cyclooxygenase activity by
inhibiting COX on the basis of bioassay-guided fractionation.1 Once more, resveratrol displays a
modulating result on lipid and lipoprotein metabolism by the blockage of lipid assimilation and
the speeding up of lipid consumption in muscles.59
Resveratrol again blocks ribonucleotide reductase, the enzyme that supplies proliferating
cells with deoxyribonucleotides necessary for DNA synthesis at its initial S-phase of the cell
cycle,60 and DNA polymerases and hinders the mitogen-activated protein kinase and protein
kinase C alleys.61 Lastly, resveratrol is a powerful activator of sirtuin activity and as a result
imitates the health benefits of caloric limitations.62Sirturns are a preserved family of NAD+dependant deacetylases and resveratrol, as a tiny molecule activator of sirtuin lengthens yeast
and other higher organisms existence on earth.
Derivatives of Resveratrol
There are several naturally occurring stilbene-like compounds that are similar to
resveratrol and also found in food. These compounds are referred to as derivatives of resveratrol
20

and an insight of the structure-activity creates new possibilities for drug discovery and other
applications. For instance, a number of acylated derivatives have revealed higher cell-growth
prevention with regard to DU- 145 human prostate cancer cells than resveratrol itself 34 due to
resveratrol’s limited bioavailability.
Methoxylated Resveratrol Derivatives
Analysis of structure-activity discovered that the substitution of hydroxyl groups of
resveratrol with methoxy groups considerably improve its cytotoxic activity.63 Therefore, some
researchers have done a lot of studies on series of methoxylated analogs of resveratrol with the
aim of increasing the antitumor activity of resveratrol. Several other stilbenes besides resveratrol,
that are similar in structure to resveratrol, occur naturally in food. An example of this is
pterostilbene (Figure 2), a dimethylated analog of resveratrol is found in blueberries that has
been studied broadly. The substitution of hydroxyl with methoxy groups increases the
lipophilicity of pterostilbene over resveratrol, resulting in better bioavailability. 64
Examples of methoxylated resveratrol derivatives shown in (Figure 2) include;

Pterostilbene

Trimethoxystilbene

Tetramethoxystilbene

Figure 2. Structure of selected methoxylated derivatives of resveratrol
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Pentamethoxystilbene

Hydroxylated Derivative of Resveratrol
A common example of a hydroxylated derivative of resveratrol is Piceatannol (3, 4, 3’, 5’tetrahydroxystilbene Figure. 3), the metabolite of resveratrol found in red wine. LMP2A, a viral
protein-tyrosinekinase linked to leukemia, Non-Hodgkin’s lymphoma, and other diseases related
to Epstein-Barr virus (EBV) also called human herpes virus4 (HHV4), was discovered to be
blocked by piceatannol in vivo. These introductory studies on piceatannol have attracted a great
deal of research interest as a potential anti-cancer and anti-EBV drug.65
Examples of hydroxylated derivatives of resveratrol shown in (Figure 3) are;

Hydroxystilbene

Dihydroxystilbene

Tetrahydroxystilbene

Figure 3. Structure of selected hydroxylated derivatives of resveratrol continued on next page
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Pentahydroxystilbene

Hexahydroxystilbene

Figure 3. Structure of selected hydroxylated derivatives of resveratrol
Other Resveratrol Derivatives
The derivatives of other resveratrol as shown in (Figure 4) include;

Resveratrol triacetate

Digalloylresveratrol

Figure 4. Structure of other derivatives of Resveratrol
23

Piceatannol

Adverse Effects and Unknowns of Resveratrol
Until now the long-term effects of using resveratrol is not known. 66 Although the health
benefits of resveratrol are remarkable, research has come out with a concept that it may promote
the development of human breast cancer cells, probably for the reason that the chemical structure
of resveratrol and phytoestrogen are alike.67 On the other hand, that research have shown that
ingestion of resveratrol reduces the risk of breast cancer in mice.68 Other research also found that
resveratrol slows down the growth of blood vessels that hold back tumors, although it delays
healing.69 From the indication that resveratrol may be estrogen detrimental, certain sellers of
resveratrol suggested that the product may meddle with oral contraceptives and that pregnant
women or women looking forward to be pregnant must not take the compound, yet a different
group also suggested that children or teenagers under 18 should not take resveratrol because
research have not shown its influence on human development. A small research work showed
that one dosage equal to 5 g of trans-resveratrol has no severe bad consequences in healthy
volunteers.70
Lipase Protection of Resveratrol Derivatives
Selectivity in the modification of many functional groups on one compound is
particularly an important objective in organic synthesis and because of that a lot of attention is
paid to research of new selective methods. It has been discovered that lipases are capable of
functioning in organic solvents, so this brings about a wide application of these biocatalysts in
organic synthesis.71-72 Lipases are enzymes that have high molecular identification potentials and
as a result can be used in the selective modification of polyhydroxylated aromatic and aliphatic
substrates. Research shows that C. Antarctica is highly specific for the phenolic group at 4’-OH,
34

because it is less sterically hindered than the 3-OH.73
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Functional Group Activity
The OH group at position 4’ (para) on resveratrol is more stable than the OH groups at
position 3 and 5 (meta) because the para position has more resonance structures than the meta.
This is shown in Scheme 1 and Scheme 2.

Scheme 1. The resonance structures of resveratrol involving abstraction of a proton from the
para-hydroxyl group
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Scheme 2. The resonance structures of resveratrol involving abstraction of a proton from the
meta-hydroxyl group
Chemical Synthesis of Resveratrol
There are various reactions used to synthesize resveratrol, but the reaction mainly used is
the decarbonylative Heck reaction. This reaction involves the chemical reaction of an
unsaturated halide with an alkene and a strong base in the presence of a palladium catalyst to
form a substituted alkene. The resveratrol acetate formed is then reacted with sodium hydroxide
in THF followed by washing with brine and water to produce resveratrol. The Heck’s reaction is
outlined in Scheme 3.
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Scheme 3. Synthesis of resveratrol using Heck’s reaction
Apart from Heck’s reaction, Perkin reaction is also another commonly used organic reaction.
The Perkin reaction is carried out by the aldol condensation of aromatic aldehydes and acids in
the presence of an alkali salt of the acid. This reaction is believed to involve fewer steps with
good percent yield (~70%). The Perkin’s reaction is outlined in Scheme 4.
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Scheme 4. The Perkins Reaction
Wittig’s reaction can also be used to synthesize resveratrol; however, it the produces a
mixture of olefin isomers.
Purpose of Research
The main aim of this research is to synthesize resveratrol derivatives, 3,5-di-Oisobutyroyl resveratrol and 3,5-Di-O-hexanoyl resveratrol using lipase catalyzed hydrolysis. This
research is to modify resveratrol to improve its low bioavailability and solubility in water.
Proposed Synthetic Pathway for Synthesis of 3,5,4’-tri-O-isobutyroyl Resveratrol
The synthesis of 3,5,4’-tri-O-isobutyroyl resveratrol was an esterification synthesis of
resveratrol as outlined in Scheme 5 and its mechanism is outlined in Scheme 6.
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Scheme 5. Synthesis of 3,5,4’-tri-O-isobutyroyl resveratrol ( Esterification)

Scheme 6. Mechanism of 3,5,4’-tri-O-isobutyroyl synthesis resveratrol using esterification of
reseveratrol
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Proposed Synthetic Pathway for Synthesis of Hexanoyl Chloride
Compound 3 was synthesized by the reaction between hexanoic acid and thionyl chloride
as shown in scheme 7. Acyl chlorides (hexanoyl chloride) are generally prepared by replacing
the equivalent hydroxy substituents with chlorides. In this reaction, the sulfur dioxide (SO2) and
hydrogen chloride (HCl) generated are both gases that can evaporate from the reaction vessel.
Excess thionyl chloride can also evaporate because the boiling point is 79oC.

Scheme 7. Synthetic pathway for hexanoyl chloride
Proposed Synthetic Pathway for Synthesis of 3,5,4’-tri-O-hexanoyl Resveratrol
The synthesis of 3,5,4’-tri-O-hexanoyl resveratrol was an esterification synthesis of
resveratrol as outlined in Scheme 8.

Scheme 8. Synthesis of 3,5,4’-tri-O-hexanoyl resveratrol (Esterification)
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Proposed Synthetic Pathway for Synthesis of 3,5-di-O-isobutyroyl Resveratrol and 3,5-di-Ohexanoyl Reseveratrol
Lipase (C. Antarctica) used in this reaction is highly specific for the phenolic group at
position 4’ because it is less sterically hindered, Scheme 9. The mechanism of this reaction is
outlined in Scheme 10.

Scheme 9. Enzymatic synthesis of 3,5-di-O-isobutyroyl resveratrol and 3,5-di-O-hexanoyl
resveratrol
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Scheme10. Mechanism of 3,5-di-O-isobutyroyl resveratrol and 3,5-di-O-hexanoyl resveratrol
32

CHAPTER 2
RESULTS AND DISCUSSION
Synthesis of 3,5,4’-tri-O-isobutyroyl Resveratrol, 2

A high yield of 90% of compound 2 was obtained as white crystals after purification of
the crude product using column chromatography. The RF value for the tri-ester was 0.67. The
triethylamine acts as a nucleophile and attacks the carbonyl carbon of the isobutyroyl chloride.
The carbonyl carbon then forms a bond with the 4’ oxygen resveratrol after the chloride ion
picks the phenol proton. The reaction continued until the phenol positions at 3 and 5 all acylated
as shown in scheme 5.
Synthesis of Hexanoyl Chloride, 3

3

Pure compound 3 was obtained as a slightly yellow liquid in 90% by reacting hexanoic
acid with thionyl chloride in dichloromethane.
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Synthesis of 3,5,4’-tri-O-hexanoyl Resveratrol, 4

4
A high yield of 95% of compound 4 was obtained as a yellow liquid after purification of
the crude product using column chromatography. The RF value for the tri-ester was 0.66. The
reason for compound 4 being a liquid is because of the long straight carbon chains on the
stilbene. This makes the compound have a large surface area that can accommodate more
interactions resulting in higher boiling point because of higher molecular weight.
Synthesis of 3,5-di-O-isobutyroyl Resveratrol, 5
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Compound 5 was obtained as white crystals with a moderate yield of 25 percent. The RF
value for the di-ester was 0.56. The n-butyl alcohol used in the reaction acted as a nucleophile.
The tert-butyl methyl ether was used as a solvent to dissolve the tri-ester. The enzyme reaction
was difficult and the low yield produced was due to very difficult separation. The 30 minutes
reaction time which was reported could not work for my compound. Several other reaction times
were tried using that same method and it became successful when the reaction was run for 24
hours. The reason for the previous unproductive method was because of the large group at the
4’position which needed much time for the reaction to go to completion. Table 1 gives the
summary of the reaction results.
Table 1. Summary of Reaction Results
Resveratrol Tri-ester Reaction Time @

Resveratrol Di-ester

Resveratrol Tri-ester

Mass (mg)

40oC , 280 rpm

Yield (%)

Recovery (%)

100 mg

30 min

None

100

100 mg

1hr

None

100

100 mg

3hrs

None

100

100 mg

9hrs

None

100

100 mg

12hrs

<1

98

100 mg

24 hrs

25

75
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Synthesis of 3,5-di-O-hexanoyl Resveratrol, 6

6
Compound 6 was obtained as white crystals after purification of the crude product using column
chromatography with a moderate yield of 41%. The RF value for the di-ester was 0.49.
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Conclusion
The objective of this research was fulfilled. The compounds, 3,5,4’-tri-O-isobutyroyl
resveratrol and 3,5,4’-tri-O-hexanoyl resveratrol have been synthesized with pure yield of 90%
and 95%, respectively. Moreover, 3,5-di-O-isobutyryl resveratrol and 3,5-di-O-hexanoyl
resveratrol, that was my main research objective, have also been successfully synthesized with
pure yields of 25% and 41%, respectively. All the compounds, 3,5,4’-tri-O-isobutyroyl
resveratrol, 3,5,4’-tri-O-hexanoyl resveratrol, 3,5-di-O-isobutyroyl resveratrol, and 3,5-di-Ohexanoyl resveratrol are new, publishable, and may be evaluated in biological systems.
The main synthetic routes used in my research were chemical and enzymatic
esterification of phenolic compounds. The disadvantage with the chemical synthesis is that a lot
of side reactions occur making it difficult to separate because it is relatively unselective. With the
enzymatic synthesis, because it is selective it has an advantage over the chemical synthesis in
that there is a minimization of side reactions making the purification steps very few. The only
problem with the enzymatic synthesis is that the yield is not as high as that of the chemical
synthesis.
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CHAPTER 3
EXPERIMENTAL
General Methods
Resveratrol and other commercial reagents were used without extra purification and they
were acquired from sigma (St. Louis, MO, USA). The data of all proton ( 1H) and (13C) NMR
spectra were taken from JEOL-NMR Eclipse spectrometer operating at 400 MHz and 100 MHz
for proton and carbon nuclei respectively. The solvents used for the spectra were CD 3COCD3,
CD3OD, and CDCl3 unless otherwise stated. Chemical shifts were recorded as delta values in
parts per million (ppm) relative to TMS. From the spectra, the multiplicity of the signals was
documented as s (singlet), d (doublet), t (triplet), h (hextet), hept (heptet), and m (multiplet).
Silica gel and suitable solvents were used in carrying out the column chromatography. Thin layer
chromatography (TLC) was done with silica gel plate using suitable solvent mixtures and viewed
under UV Fluorescent indicator. Melting points for the crystals were recorded using Cambridge
MEL-TEMP instrument. All weighing was performed on Mettler PJ360 Delta Range scale unless
otherwise stated.
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Experimental Procedures
Synthesis of 3,5,4’-tri-O-isobutyroyl Resveratrol

Resveratrol (1.04 g, 4.56 mmol) was dissolved in acetone (35 mL) acting as the solvent,
and isobutyroyl chloride (1.46 g, 13.68 mmol ) and triethylamine ( 1.38 g, 13.68 mmol) were
added to it and stirred in a 50-mL round bottom flask for 12 hours. The solution was then
acidified (≤5) with hydrochloric acid (2N). The crude product was extracted in the organic layer
by means of ethyl acetate (2×35 mL). The excess hydrochloric acid was removed by washing
with sodium hydrocarbonate (35 mL). The product was dried by means of magnesium sulfate
followed by gravity filtration. The crude product was purified again using column
chromatography. Melting point of pure compound was 85oC – 87oC.
1

HNMR (CD3OD/CD3COCD3, 400MHZ, ppm) δ1.27 (d1, 18H, CH3); δ 2.84 (m, 3H, CH); δ 6.71

(dd1, 1H, Ar-H); δ 6.78 (d1, 1H, CH=C); δ 7.26 (dd1, 2H, Ar-H); δ 7.00 (d1, 1H, CH=C); δ 7.12
(ddd1, 2H, Ar-H); δ 7.41 (ddd1, 2H, Ar-H) 13CNMR (CD3OCD3,100 MHz, ppm) δ 18.32, 34.01,
114.87, 116.99, 122.15, 127.06, 127.70, 129.60, 134.60, 139.74, 151.07, 151.98, 174.67, 174.89
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Synthesis of Hexanoyl Chloride

Hexanoic acid (4 mL, 32 mmol) was put in a 25-mL round bottomed flask in addition
with 5 mL dichloromethane. Thionyl chloride (4.64mL, 64 mmol) was added drop wise and
stirred for an hour for the gases to escape. The mixture was put in an oil bath at 50 oC for
additional hour to allow all the gas to evaporate. The mixture was then distilled to first collect the
dichloromethane and then excess thionyl chloride (boiling point, 79 oC) and lastly hexanoyl
chloride (boiling point, 151-153oC). A dark brown liquid residue was left behind. 1HNMR
(400MHz, CDCl3, ppm) δ 0.81 (t 1, 3H, CH3); δ 1.23 (h, 2H, CH2); δ 1.23 (tt1, 2H, CH2); δ 1.59
(tt1, 2H, CH2); δ 2.77 (t1, 2H, CH2)
Synthesis of 3,5,4’-tri-O-hexanoyl Resveratrol

Resveratrol (1.00 g, 4.386 mmol) was dissolved in acetone (33 mL) and hexanoyl
chloride (1.771 g, 13.158 mmol ) and triethylamine ( 1.331 g, 13.158 mmol) were added and
stirred in a 50-mL round bottom flask for 12 hours. The solution was then acidified with
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hydrochloric acid (2N). The crude product was extracted with ethyl acetate (2×33 mL). The
excess hydrochloric acid was removed by washing the organic layer with saturated sodium
hydrocarbonate (33 mL) and drying over magnesium sulfate followed by gravity filtration. The
crude product was obtained by evaporation of solvent and was purified using column
chromatography. 1HNMR (CD3COCD3, 400MHz, ppm) δ0.90 (t 1, 9H, CH3); δ 1.37 (m, 6H,
CH2); δ 1.37 (tt1, 6H, CH2); δ 1.71 (tt 1, 6H, CH2); δ 2.57 (t1, 6H, CH2); δ 6.84 (t1, 1H, Ar-H); δ
7.23 (d1, 1H, CH=C); δ 7.14 (dd1, 2H, Ar-H); δ 7.24 (d1, 1H, CH=C); δ 7.25 (ddd1, 2H, Ar-H); δ
7.65 (ddd1, 2H, Ar-H) 13CNMR (CDCl3,100 MHz, ppm) δ 13.61, 22.01, 25.00, 31.50, 34.10,
115.14, 117.22, 122.40, 127.27, 127.90, 129.78, 134.77, 139.92, 151.17, 152.06, 171.60, 171.79
Synthesis of 3,5-di-O-isobutyroyl Resveratrol

3,5,4’-tri-O-isobutyroyl resveratrol (100 mg, 0.023 µmol) was dissolved in t-butyl methyl
ether (5 mL, 42 mmol) in 25-mL round bottom flask. A mixture containing C. Antarctica (100
mg) and n-butyl alcohol (0.4 mL) was added to the round bottom flask. The mixture was stirred
by the help of a rotovap (40oC, 280 rpm) for 24 hrs. After 24 hrs, the enzyme was filtered and the
filtrated was left to evaporate leaving behind the crude product. The crude product was purified
by the use of column chromatography. Melting point of pure product was 142oC – 145oC.
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1

HNMR (CD3OD 400MHZ, ppm) δ1.29 (d1, 12H, CH3); δ 2.81 (m, 2H, CH); δ 6.71 (dd1, 1H,

Ar-H); δ 6.78 (ddd1, 2H, Ar-H); δ 7.00 (ddd1, 1H, Ar-H); δ 7.10 (dd1, 2H, Ar-H); δ 7.11 (d1,
1H, C=CH); δ 7.12 (d1, 1H, C=CH ) δ 7.41 (ddd1, 1H, Ar-H) 13CNMR (CD3OD,100 MHz,
ppm) δ 17.93, 33.98, 113.50, 115.23, 116.23, 123.53, 127.97, 128.49, 130.49, 151.75, 158.06,
175.58
Synthesis of 3,5-di-O-hexanoyl Resveratrol

3,5,4’-tri-O-hexanoyl resveratrol (0.743 g, 1.423 mmol) was put in a 100-mL round
bottom flask together with “t”-butyl methyl ether (37.2 mL, 0.313 mol). A mixture containing C.
Antarctica (0.743 g) and n-butyl alcohol (3.0 mL) was added to the round bottom flask. The
mixture was stirred by the help of a rotovap (40oC, 280 rpm) for 24 hrs. After 24 hrs, the enzyme
was filtered and the filtrated was left to evaporate leaving behind the crude product. The crude
product was purified by the use of column chromatography. Melting point of pure product was
98oC – 100oC. 1HNMR (CD3COCD3, 400MHZ, ppm) δ0.90 (t 1, 6H, CH3); δ 1.37 (m, 4H, CH2);
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δ 1.37 (tt1, 4H, CH2); δ 1.71 (tt1, 4H, CH2); δ 2.59 (t1, 4H, CH2); δ 6.80 (dd1, 1H, Ar-H); δ 7.06
(d1, 1H, CH=C); δ 6.86 (dd1, 2H, Ar-H); δ 7.19 (d1, 1H, CH=C); δ 7.46 (ddd1, 2H, Ar-H); δ
7.48 (ddd1, 2H, Ar-H); δ 8.59 (s, 1H, OH) 13CNMR (CDCl3,100 MHz, ppm) δ 13.42, 22.00,
24.50, 31.00, 33.50, 114.28, 115.59, 115.68, 116.61, 123.96, 128.30, 128.62, 130.46, 140.33,
151.84, 157.83, 171.41
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